Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2113017?articleTools=true RESULTS: The trial enrolled 30,415 participants; 15,209 were assigned to receive the mRNA-1273 vaccine, and 15,206 to receive placebo. More than 96% of participants received both injections, 2.3% had…
